CT.gov No. | Phase | Investigational Agent | Trial | Setting | n | Completion Date |
---|---|---|---|---|---|---|
NCT02620280 | III | Atezolizumab | Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin (NeoTRIPaPDL1) | Neoadjuvant TNBC | 272 | 2022 |
NCT02425891 | III | Atezolizumab | A study of atezolizumab in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for participants with previously untreated metastatic triple negative breast cancer (IMpassion130) | mTNBC | 900 | 2020 |
NCT02819518 | III | Pembrolizumab | A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) | Locally recurrent or metastatic BC | 858 | 2019 |
NCT01690702 | III | Epirubicin, Cyclophosphamide Docetaxel | Adjuvant Phase III Trial to Compare Intense Dose-dense Adjuvant Treatment With EnPC to Dose Dense, Tailored Therapy With dtEC-dtD for Patients With High-risk Early Breast Cancer (GAIN-2) | Adjuvant high risk BC | 2886 | 2020 |
CBCSG018 | II | Gemcitabine | A randomized phase 2 trial of weekly nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment for patients with metastatic triple-negative breast cancer | mTNBC | 254 | 2018 |
Cisplatin | ||||||
NCT02685059 | II | Durvalumab | A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo) | Neoadjuvant TNBC | 174 | 2018 |
NCT02783222 | II | nab-paclitaxel | A Randomized Phase II Study to Evaluate the EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly Patients With advanCed breasT Cancer (EFFECT) | ≥65y Locally recurrent or metastatic BC | 156 | 2017 |